Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532232 · ClinicalTrials.gov registry record
Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- 7
- Enrollment target
NCT01532232: Clinical Trial study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01532232 is a clinical trial that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01532232 was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
Breast cancer patients who smoke, are at greater risk for treatment complications. The purpose of this study is to see if the researchers can find ways to help patients who have breast cancer quit smoking. They will compare two ways to help people quit smoking. Some patients will receive varenicline, a prescription medicine also known as Chantix,®. Other patients will receive a placebo drug. A placebo is an inactive substance that contains no medicine. All patients will receive smoking cessation counseling provided by our tobacco treatment specialists. They hope that what the researchers learn from this study will help us improve our smoking cessation treatment program for breast cancer patients.
Primary Outcome
To conduct a double-blind, randomized clinical trial to obtain pilot data on the the effectiveness of Intervention (varenicline and behavioral smoking cessation counseling) and Control (placebo and behavioral smoking cessation counseling) with regard to tobacco (smoking) cessation outcomes (point abstinence, continuous abstinence) in tobaccodependent breast cancer patients.
Interventions
- DRUG placebo
- DRUG varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-10 |
Why NCT01532232 stopped before completion
NCT01532232 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01532232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01532232 about?
NCT01532232 is a clinical study titled "Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)". Breast cancer patients who smoke, are at greater risk for treatment complications. The purpose of this study is to see if the researchers can find ways to help patients who have breast cancer quit smoking. They will compare two ways to help people quit smoking. Some patients will receive varenicline...
What is the current status of trial NCT01532232?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2012-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01532232?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG).
Who is sponsoring clinical trial NCT01532232?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia